查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836807

帕金森氏症治療市場（按藥物類別、治療類型、給藥途徑、目標區域、分銷管道和最終用戶分類）—2025-2030 年全球預測

Parkinson's Disease Therapeutics Market by Drug Class, Therapy Type, Route Of Administration, Targeted Area, Distribution Channel, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2030 年，帕金森氏症治療市場規模將成長至 78.3 億美元，複合年成長率為 6.29%。

主要市場統計數據
基準年2024年 54.3億美元
預計2025年 57.6億美元
預測年份 2030 78.3億美元
複合年成長率（%） 6.29%

關於帕金森氏症治療的複雜性、每個階段未滿足的需求以及臨床開發和商業性成功的策略重點的權威框架

帕金森氏症是臨床醫生、研究人員、支付者和產業面臨的最複雜的神經退化性疾病之一。過去十年，治療發展已從針對症狀的單一標靶療法轉向結合複雜多巴胺能調節、神經保護假設和支持性非藥物干預的整合策略。本簡介總結了當前的治療前景，識別了不同疾病階段的未滿足臨床需求，並組裝了策略要點，以指南決策者評估投資、臨床專案設計和投資組合優先順序。

新興臨床證據和現實世界模式揭示了差距，也揭示了機會。雖然左旋多巴持續支持運動症狀控制，但長期運動併發症、異質性非運動症狀負擔以及患者反應差異凸顯了對多樣化治療模式的需求。同時，治療創新和多學科護理模式有望改善功能和生活品質。這些動態共同要求對療效、持久性、耐受性、給藥便利性和系統級採用途徑等方面的治療價值有細緻的理解。本介紹為深入探討不斷變化的格局、政策影響、細分資訊、區域差異以及為尋求駕馭快速發展的治療生態系統的行業領導者提供實用建議奠定了基礎。

科學進步、精準表現型分析和現實世界證據如何重塑帕金森氏症治療並創造新的策略曲折點

在科學進步、護理標準不斷改進以及跨部門合作的推動下，帕金森氏症的治療模式正在發生重大變化。近年來，該領域在藥物類別、輔助性治療和基於設備的給藥平台方面創新加速，促使人們重新思考臨床路徑和治療順序。患者表現型分析的精準度提高以及生物標記的使用改善了臨床試驗的入組和療效解讀，而神經調節和康復方面的進步則提升了非藥物干預措施的作用，使其不再僅僅作為輔助手段，而是成為重要的補充手段。

同時，真實世界證據生成和自適應試驗設計正在縮短開發週期，並加快後期專案的「可行/不予批准」決策。醫療保健系統的相關人員越來越關注患者重要的臨床結果，例如日常生活活動能力和看護者負擔，導致在臨床開發和報銷討論中廣泛接受多方面終點。因此，將轉化科學與務實的部署策略和相關人員一致的證據計劃相結合的公司將更有能力獲得臨床和經濟價值。本節詳細介紹了這種轉變模式，並指出了產業相關人員應密切關注的關鍵曲折點。

對 2025 年美國關稅變化將如何再形成治療供應鏈彈性、定價壓力和商業化策略的定性分析

在近期政策週期中，新關稅政策和貿易措施的訂定，使全球製藥和醫療設備製造商的供應鏈規劃變得複雜。美國宣布了截至2025年的累積關稅調整，迫使製造商重新評估其採購、庫存策略以及帕金森氏症治療中常用的原料、成品和器械組件的定價方法。本節將分析關稅動態影響產業經濟和營運韌性的定性機制，避免進行推測性的量化分析。

關稅造成的成本壓力往往會波及整個製造和分銷鏈。當進口關稅影響到輸液幫浦和輸送系統的原料、輔料或專用零件時，製造商面臨權衡取捨：將成本轉嫁給付款人和患者，吸收利潤壓縮，還是轉移生產。物流複雜性和海關手續可能會延長前置作業時間，從而增加對安全庫存和靈活供應協議的需求。此外，關稅波動會帶來採購風險，可能抑制對資本密集型項目的投資，並推遲商業化時程。從付款人和提供者的觀點來看，增加的購買成本可能會使處方提案轉向具有差異化價值主張的產品，這些產品具有臨床益處或降低總護理成本的合理性。

為了緩解這些不利因素，企業正在實現供應商多元化，將關鍵製造流程近岸外包，並尋求簽訂長期採購協議。針對替代生產地點的監管和品質調整也在加速進行，以保持供應的連續性。摘要，到2025年，關稅的變化強化了對一體化供應鏈策略的需求，該策略將製造地決策與臨床開發和商業化計劃相結合，確保企業具備韌性並持續創新。

利用藥物類別、治療方式、給藥途徑、患者亞型、分銷管道和最終用戶設定的關鍵細分資訊來完善您的策略

穩健的細分市場對於帕金森氏症治療的有效開發和商業化策略至關重要。在以藥物類別檢視市場時，相關人員應認知到抗膽鹼能藥物（包括苯扎托品和苯海索）以及 COMT 抑制劑、多巴胺促效劑、左旋多巴和 MAO-B 抑制劑的獨特臨床特徵和定位。在按治療方法類型細分時，傳統藥物介入和非藥物療法（例如深部腦部刺激、物理治療以及言語和語言治療）在整個疾病過程中發揮越來越重要的策略作用，影響著依從性、療效和付款人的接受度。

依給藥途徑細分可揭示輸注、注射、口服和經皮劑型如何在起效時間、病患便利性和看護者負擔方面創造不同的價值提案。非典型、藥物誘發、遺傳、特發性和血管性帕金森氏症的目標區域分類顯示疾病病因的異質性，臨床開發必須根據病理學和進展模式進行量身定做。分銷通路觀點將線下模式（例如醫院藥局和零售藥局）與線上藥局區分開來，每個通路都決定病患的取得、依從性支援和商業性參與策略。最後，最終用戶細分（包括診所、居家照護和醫院）突顯了產品採用如何取決於工作流程、報銷途徑和護理環境提供專業服務的能力。整合這些細分使發起人能夠確定開發資產的優先級，產生有針對性的證據，並制定與臨床相關人員和付款人產生共鳴的差異化發布策略。

美洲、中東和非洲以及亞太地區的區域動態和付款人格局將決定獲取、採用和商業策略

區域動態對治療方案的採用、監管時間表和付款人期望有重大影響。在美洲，人口老化和成熟的專科護理網路推動了對藥物和器械解決方案的需求，而付款人生態系統則強調報銷決策中的比較有效性以及影響預算的證據。跨境製造和分銷實踐進一步影響了藥品的供應和物流，該地區的相關人員通常優先考慮快速獲取途徑和基於價值的合作合約模式。

在歐洲、中東和非洲，多樣化的法規結構和差異化的報銷格局為差異化策略的實施既帶來了障礙，也帶來了機會。西歐的高所得市場通常需要完善的衛生技術評估方案和實際結果，而更廣泛地區的新興市場則可能優先考慮可擴展、經濟高效的干涉措施和簡化的交付模式。由於地區間在專科醫生和基礎設施取得方面的差異，投資於與當地衛生系統的夥伴關係和能力建設對於有效採用差異化策略至關重要。

在亞太地區，創新醫療服務技術的快速普及以及政府對本土製造業的大力支持，正在塑造競爭動態。人口和流行病學趨勢，加上私人和公共支付方日益成熟的技術，正在推動獨特的定價和上市策略。這些地區差異共同要求制定適應性強的上市計劃、有針對性的證據生成以及反映當地醫療保健路徑和決策流程的相關人員參與模式。

競爭動態、生物製藥和設備創新者之間的合作以及基於結果的方法如何重新定義企業策略和差異化

隨著現有產品線面臨來自新機制、增強型給藥系統和整合照護模式的壓力，帕金森氏症治療領域的競爭態勢正在不斷演變。先前主導多巴胺能藥物治療的老牌製造商如今正與推進緩解疾病理念的生物技術公司以及提供下一代神經調節和輸注技術的醫療技術公司競爭。策略聯盟和許可協議正在彌合分子創新與基於設備的治療方法之間的差距，創造出吸引尋求改善症狀控制和減輕治療負擔的臨床醫生和患者的混合價值提案。

商業環境也反映出對核准後證據產生的日益重視，付款方越來越要求透過實際結果和註冊記錄來證明長期效益。早期投資於基於結果的合約和患者支持基礎設施的公司，能夠提高其獲得有利處方集的幾率。此外，專注於簡化給藥、提供看護者支援以及與居家照護模式整合的製造商，將在日益擴張的門診病人護理環境中獲得競爭優勢。總體而言，該領域的領導者正在透過整合強大的臨床數據、周到的通路策略和夥伴關係關係，同時應對諸如勞動力限制和成本控制壓力等機構挑戰，加速在醫療保健環境中的採用。

為產業領導者提供實用的策略方法，以協調生物標記驅動的開發、彈性供應鏈和結果驅動的商業化

業界領導者應採取切實可行的舉措，將科學機會與實際的醫療服務和報銷現實相結合。首先，將轉化生物標記計畫整合到研發計畫中，可以改善患者分層，並提高監管機構和付款方接受標靶治療的可能性。其次，建立靈活的生產佈局和供應商冗餘可以緩解外部衝擊，例如關稅變化和零件短缺，同時保持產品上市時間表和准入承諾。第三，制定結合隨機、實用化和真實世界臨床試驗的跨職能證據計劃，可以解決從監管機構到付款方再到臨床醫生等廣泛相關人員的擔憂。

領導者還應優先考慮在臨床、技術和服務領域建立夥伴關係，以加快價值實現速度。與設備開發商、數位醫療公司和復健專家合作，可以打造差異化的照護方案，以更好地滿足患者需求。同時，積極與付款方溝通，探索基於結果的報銷和試驗計畫，可以減少實施過程中的摩擦。最後，投資病人和看護者的支援服務，可以提高依從性，並展現對現實世界影響的承諾。這些行動共同創造持久的差異化，並有助於將科學進步轉化為永續的臨床和商業性成功。

一種透明的調查方法，結合主要專家訪談、二手科學資訊和情境分析來檢驗策略見解和局限性

本研究整合了原始數據和二手數據，為嚴謹、可複製的方法論奠定了基礎。原始資料收集包括與臨床專家、藥劑師、付款人代表和行業相關人員進行結構化訪談，以了解現實世界中關於治療方法使用、獲取障礙和證據需求的觀點。二手資料分析將研究結果與同行評審文獻、監管文件、臨床試驗註冊中心和公共文件進行三角檢驗，以確保科學準確性。我們的分析方法將定性主題編碼與情境分析相結合，以評估監管變化、供應鏈動態和相關人員期望的影響。

透明度和檢驗貫穿整個研究過程。關鍵見解與多個獨立資訊來源進行了交叉核對，並在可能的情況下與臨床醫生和衛生系統決策者檢驗。我們承認存在局限性：快速發展的臨床數據和政策發展需要定期更新，並且某些操作變數可能因特定國家/地區而異。然而，本調查方法提供了一種實用的綜合方法，以支持策略決策，幫助確定證據生成的優先順序，並為不同治療模式和地區的商業化和可及性策略提供資訊。

整合策略要務，將科學創新與實際商業化和獲取策略結合，以產生病患影響

帕金森氏症治療領域正處於曲折點，科學進步、給藥創新和不斷變化的相關人員期望交織在一起。藥理學的進步，加上更強大的劑型和非藥物干預措施，正在為全面治療運動和非運動症狀創造機會。然而，新興的政策壓力、供應鏈的複雜性以及患者亞型的異質性，正挑戰企業採取整合策略，將臨床開發與實際的商業化和可及性考量相結合。

成功的策略在於平衡嚴謹的證據產生、營運韌性和相關人員的參與。那些優先考慮以患者為中心的成果、投資靈活的生產和供應解決方案並製定本地化上市計劃的公司，最有能力將創新轉化為有意義的臨床影響。最終，成功之路在於將科學嚴謹性與實際執行相結合，確保治療進展能夠高效、永續地惠及患者，同時滿足臨床醫生、付款人和醫療系統的期望。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 旨在阻止帕金森氏症進展的基因治療技術的出現
  • 擴大針對神經再生的幹細胞治療研究
  • 帕金森氏症治療中個人化醫療的應用日益增多
  • 非侵入性腦部刺激在症狀管理的進展
  • 人們越來越關注旨在改善治療結果的早期診斷生物標記物
  • 開發新型藥物輸送系統以增強治療效果
  • 增加對神經保護藥物的投資以減緩疾病進展
  • 探索微生物組對帕金森氏症治療方法的影響
  • 整合數位健康技術，實現遠端患者監護
  • 國際合作臨床試驗加速醫藥品認證過程

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 帕金森氏症治療市場（依藥物類別）

  • 抗膽鹼藥物
    • 苯扎托品
    • 苯海索
  • COMT抑制劑
    • entacapone
    • 託卡朋
  • 促效劑
  • 左旋多巴
  • MAO-B抑制劑

9. 帕金森氏症治療市場（依治療類型）

  • 製藥
  • 非藥物治療
    • 深部腦部刺激
    • 物理治療
    • 言語和聲音治療

10. 帕金森氏症治療市場（依給藥途徑）

  • 注射
  • 注射
  • 口服
  • 經皮

第 11 章：帕金森氏症治療市場（按目標區域）

  • 非典型帕金森氏症
  • 藥物誘發的帕金森氏症
  • 遺傳性帕金森氏症
  • 特發性帕金森氏症
  • 血管性帕金森氏症

12. 帕金森氏症治療市場（按分銷管道）

  • 離線
    • 醫院藥房
    • 零售藥局
  • 線上

第 13 章：帕金森氏症治療市場（以最終用戶分類）

  • 診所
  • 居家護理
  • 醫院

第 14 章：帕金森氏症治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 15 章帕金森氏症治療市場（按群體）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 16 章：帕金森氏症治療市場（按國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AbbVie Inc.
    • Biogen Inc.
    • Bristol-Myers Squibb Company
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Otsuka Pharmaceutical Co., Ltd.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Limited
    • Bayer AG
Product Code: MRR-036C5CF3B54D

The Parkinson's Disease Therapeutics Market is projected to grow by USD 7.83 billion at a CAGR of 6.29% by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 5.43 billion
Estimated Year [2025] USD 5.76 billion
Forecast Year [2030] USD 7.83 billion
CAGR (%) 6.29%

An authoritative framing of Parkinson's therapeutic complexity, unmet needs across stages, and strategic priorities for clinical development and commercial success

Parkinson's disease remains one of the most complex neurodegenerative disorders confronting clinicians, researchers, payers, and industry alike. Over the last decade, therapeutic development has shifted from symptomatic mono-target approaches toward integrated strategies that combine refined dopaminergic modulation, neuroprotective hypotheses, and supportive non-pharmacological interventions. This introduction synthesizes the current therapeutic posture, clarifies unmet clinical needs across disease stages, and frames the strategic imperatives that should guide decision-makers when evaluating investment, clinical program design, or portfolio prioritization.

Emerging clinical evidence and real-world practice patterns have both exposed gaps and revealed opportunities. While levodopa continues to underpin motor symptom control, long-term motor complications, heterogeneity in non-motor symptom burden, and differential patient responses highlight the need for diversified treatment paradigms. Concurrently, innovations in delivery technologies and multidisciplinary care models have shown promise in improving function and quality of life. Taken together, these dynamics demand a nuanced understanding of therapeutic value that spans efficacy, durability, tolerability, ease of administration, and system-level adoption pathways. This introduction sets the stage for a deeper examination of landscape shifts, policy impacts, segmentation intelligence, regional nuances, and practical recommendations for industry leaders seeking to navigate a rapidly evolving therapeutic ecosystem.

How scientific advances, precision phenotyping, and real-world evidence are reshaping Parkinson's care delivery and creating new strategic inflection points

The therapeutic landscape for Parkinson's disease is undergoing transformative shifts driven by scientific advances, evolving standards of care, and cross-sector collaboration. Over recent years, the field has witnessed accelerated innovation in drug classes, adjunctive therapies, and device-enabled delivery platforms, prompting a reassessment of clinical pathways and treatment sequencing. Precision in patient phenotyping and biomarker use has improved trial enrolment and response interpretation, while advances in neuromodulation and rehabilitation are elevating the role of non-pharmacological interventions as essential complements rather than mere adjuncts.

Simultaneously, real-world evidence generation and adaptive trial designs are shortening development cycles and enabling more responsive go/no-go decisions for late-stage programs. Health-system stakeholders are increasingly focused on outcomes that matter to patients, such as activities of daily living and caregiver burden, which has led to wider acceptance of multidimensional endpoints in clinical development and reimbursement discussions. As a result, companies that integrate translational science with pragmatic deployment strategies and stakeholder-aligned evidence plans will be better positioned to capture clinical and economic value. This section elaborates on these paradigm changes and identifies the critical inflection points that industry players should monitor closely.

Qualitative analysis of how United States tariff shifts through 2025 reshape supply chain resilience, pricing pressure, and commercialization strategies in therapeutics

The introduction of new tariff policies and trade measures in recent policy cycles has complicated supply chain planning for global pharmaceutical and device manufacturers. In the United States context, cumulative tariff adjustments announced through 2025 have prompted manufacturers to reassess sourcing, inventory strategy, and pricing approaches for components, finished dosage forms, and device elements commonly used in Parkinson's therapeutics. This section analyzes the qualitative mechanisms through which tariff dynamics influence industry economics and operational resilience, while avoiding speculative quantification.

Tariff-induced cost pressures often cascade across manufacturing and distribution chains. When import duties affect raw materials, excipients, or specialized components for infusion pumps or delivery systems, manufacturers face trade-offs between passing costs to payers and patients, absorbing margin compression, or relocating production. Logistics complexity and customs processing can extend lead times, increasing the need for safety stocks and flexible supply agreements. Moreover, tariff volatility introduces procurement risk that can dampen investment in capital-intensive programs or delay commercialization timelines. From a payer and provider perspective, increased acquisition costs can shift formulary decisions and favor products with differentiated value propositions justified by clinical benefits or lower total cost of care.

To mitigate these headwinds, companies are increasingly pursuing supplier diversification, nearshoring of critical manufacturing steps, and longer-term procurement contracts. They are also accelerating regulatory and quality alignment for alternate production sites to preserve continuity of supply. In summary, tariff shifts through 2025 have reinforced the imperative for integrated supply chain strategies that align manufacturing footprint decisions with clinical development and commercialization plans, ensuring both resilience and the ability to sustain innovation.

Key segmentation intelligence across drug classes, therapy modalities, administration routes, patient subtypes, distribution channels, and end-user settings to sharpen strategy

Robust segmentation is central to effective development and commercialization strategies for Parkinson's therapeutics. When examining the market by drug class, stakeholders should recognize the distinct clinical profiles and positioning of Anticholinergics, which include Benztropine and Trihexyphenidyl, alongside COMT inhibitors, Dopamine agonists, Levodopa, and MAO-B inhibitors, each of which addresses different symptom clusters and long-term management questions. Therapy type segmentation separates traditional pharmacologic interventions from Non-Pharmacological Therapies where modalities such as Deep Brain Stimulation, Physiotherapy, and Speech & Language Therapy play increasingly strategic roles across disease stages, influencing adherence, outcomes, and payer acceptance.

Route of administration segmentation highlights how infusion, injectable, oral, and transdermal formats create distinct value propositions related to onset of action, patient convenience, and caregiver burden. Targeted area classification-spanning Atypical Parkinsonian, Drug-Induced Parkinsonism, Genetic Parkinson's, Idiopathic Parkinson's, and Vascular Parkinsonism-underscores the heterogeneity of etiologies and the implication that clinical development must be tailored to pathophysiology and progression patterns. Distribution channel perspectives differentiate Offline models such as Hospital Pharmacy and Retail Pharmacy from Online Pharmacy, with each channel dictating distinct patient access, adherence support, and commercial engagement tactics. Finally, end-user segmentation that includes Clinics, Home Care, and Hospitals emphasizes that product adoption hinges on workflows, reimbursement pathways, and the capacity of care settings to deliver specialized services. Integrating these segmentation lenses enables sponsors to prioritize development assets, design targeted evidence generation, and craft differentiated launch strategies that resonate with clinical and payer stakeholders.

Regional dynamics and payer landscapes across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access, adoption, and commercial strategy

Regional dynamics exert significant influence on therapeutic adoption, regulatory timelines, and payer expectations. In the Americas, demographic aging and well-established specialty care networks drive demand for both pharmacologic and device-based solutions, while payer ecosystems emphasize comparative effectiveness and budget impact evidence in reimbursement decisions. Cross-border manufacturing and distribution practices further shape availability and logistics, and stakeholders in this region often prioritize rapid access pathways and collaborative value-based contracting models.

Across Europe, Middle East & Africa, diverse regulatory frameworks and heterogeneous reimbursement landscapes create both obstacles and opportunities for differentiated strategies. High-income markets in Western Europe typically demand robust health technology assessment packages and real-world outcomes, whereas emerging markets in the broader region may value scalable, cost-effective interventions and simplified delivery models. Regional disparities in specialist access and infrastructure mean that partnerships with local health systems and investment in capacity-building are critical for meaningful adoption.

In the Asia-Pacific region, rapid adoption of innovative delivery technologies and strong governmental support for domestic manufacturing are shaping competitive dynamics. Demographic and epidemiological trends, combined with growing private and public payer sophistication, incentivize tailored pricing and market access approaches. Taken together, these regional nuances require adaptive go-to-market plans, targeted evidence generation, and stakeholder engagement models that reflect local care pathways and decision-making processes.

How competitive dynamics, alliances between biologics and device innovators, and outcomes-based approaches are redefining company strategies and differentiation

Competitive dynamics in Parkinson's therapeutics are evolving as incumbent product lines face pressure from novel mechanisms, enhanced delivery systems, and integrated care models. Established manufacturers that have historically dominated dopaminergic therapies are now contending with biotech entrants advancing disease-modifying concepts, as well as medtech firms delivering next-generation neuromodulation and infusion technologies. Strategic alliances and licensing transactions increasingly bridge gaps between molecular innovation and device-enabled delivery, creating hybrid value propositions that appeal to clinicians and patients seeking improved symptom control and reduced treatment burden.

The operating landscape also reflects a rising emphasis on post-approval evidence generation, as payers request real-world outcomes and registries to demonstrate longitudinal benefit. Companies that invest early in outcomes-based agreements and patient support infrastructure improve the probability of favorable formulary positioning. Additionally, manufacturers focusing on ease of administration, caregiver support, and integration with home-care models gain competitive advantage in settings where outpatient management is expanding. Overall, leaders in this space combine strong clinical data, thoughtful channel strategies, and partnerships that accelerate adoption across care settings while addressing systemic challenges such as workforce limitations and cost containment pressures.

Practical strategic initiatives for industry leaders to align biomarker-enabled development, resilient supply chains, and outcomes-driven commercialization

Industry leaders should adopt actionable initiatives that align scientific opportunity with pragmatic delivery and reimbursement realities. First, integrating translational biomarker programs with development plans will improve patient stratification and increase the likelihood of regulatory and payer acceptance for targeted therapies. Second, building flexible manufacturing footprints and supplier redundancy helps mitigate external shocks such as tariff shifts or component shortages, preserving launch timelines and access commitments. Third, cultivating cross-functional evidence plans that combine randomized trials, pragmatic studies, and real-world registries will address the broad spectrum of stakeholder concerns from regulators to payers and clinicians.

Leaders should also prioritize partnerships across clinical, technological, and service domains to accelerate time-to-value. Collaborations with device developers, digital health firms, and rehabilitation specialists can create differentiated, bundled care offerings that better meet patient needs. In parallel, proactive engagement with payers to explore outcomes-based reimbursement and pilot programs can reduce adoption friction. Finally, investing in patient and caregiver support services enhances adherence and demonstrates commitment to real-world impact. Collectively, these actions create durable differentiation and position organizations to convert scientific progress into sustainable clinical and commercial success.

A transparent research methodology combining primary expert interviews, secondary scientific sources, and scenario analysis to validate strategic insights and limitations

This research synthesizes primary and secondary sources to create a rigorous, reproducible methodological foundation. Primary data collection included structured interviews with clinical experts, pharmacists, payer representatives, and industry stakeholders to capture real-world perspectives on therapeutic use, access barriers, and evidence needs. Secondary analysis drew on peer-reviewed literature, regulatory submissions, clinical trial registries, and public policy documents to triangulate findings and ensure scientific fidelity. Analytical approaches combined qualitative thematic coding with scenario analysis to evaluate the implications of regulatory changes, supply chain dynamics, and stakeholder expectations.

Throughout the research, emphasis was placed on transparency and validation. Key insights were cross-checked against multiple independent sources and, where possible, validated with clinicians and health-system decision-makers. Limitations are acknowledged: rapidly evolving clinical data and policy developments require periodic updates, and some operational variables may differ across specific national contexts. Nonetheless, the methodology delivers an actionable synthesis that supports strategic decision-making, helps prioritize evidence generation, and informs commercialization and access strategies across therapeutic modalities and geographies.

A synthesis of the strategic imperative to combine scientific innovation with pragmatic commercialization and access strategies to deliver patient impact

The therapeutic environment for Parkinson's disease is at an inflection point where scientific progress, delivery innovation, and shifting stakeholder expectations converge. Advances in pharmacology are being complemented by enhanced delivery formats and non-pharmacological interventions, creating opportunities to address both motor and non-motor symptoms more comprehensively. However, new policy pressures, supply chain complexities, and the heterogeneity of patient subtypes demand that companies adopt integrated strategies that align clinical development with pragmatic commercialization and access considerations.

Successful strategies will balance rigorous evidence generation with operational resilience and stakeholder engagement. Firms that prioritize patient-centered outcomes, invest in flexible manufacturing and supply solutions, and craft regionally adapted market access plans are best positioned to translate innovation into meaningful clinical impact. In closing, the pathway to success lies in combining scientific rigor with pragmatic execution, ensuring that therapeutic advances reach patients efficiently and sustainably while meeting the expectations of clinicians, payers, and health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of gene therapy techniques aiming to halt Parkinson's disease progression
  • 5.2. Expansion of stem cell therapy research targeting neuronal regeneration
  • 5.3. Increasing adoption of personalized medicine in Parkinson's disease treatment
  • 5.4. Advancements in non-invasive brain stimulation therapies for symptom management
  • 5.5. Growing focus on early diagnostic biomarkers to improve treatment outcomes
  • 5.6. Development of novel drug delivery systems enhancing therapeutic efficacy
  • 5.7. Rising investment in neuroprotective agents to slow disease advancement
  • 5.8. Exploration of microbiome influence on Parkinson's disease therapeutic approaches
  • 5.9. Integration of digital health technologies for remote patient monitoring
  • 5.10. Collaborative global clinical trials accelerating drug approval processes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Parkinson's Disease Therapeutics Market, by Drug Class

  • 8.1. Anticholinergics
    • 8.1.1. Benztropine
    • 8.1.2. Trihexyphenidyl
  • 8.2. COMT Inhibitors
    • 8.2.1. Entacapone
    • 8.2.2. Tolcapone
  • 8.3. Dopamine Agonists
  • 8.4. Levodopa
  • 8.5. MAO-B Inhibitors

9. Parkinson's Disease Therapeutics Market, by Therapy Type

  • 9.1. Medications
  • 9.2. Non-Pharmacological Therapies
    • 9.2.1. Deep Brain Stimulation
    • 9.2.2. Physiotherapy
    • 9.2.3. Speech & Language Therapy

10. Parkinson's Disease Therapeutics Market, by Route Of Administration

  • 10.1. Infusion
  • 10.2. Injectable
  • 10.3. Oral
  • 10.4. Transdermal

11. Parkinson's Disease Therapeutics Market, by Targeted Area

  • 11.1. Atypical Parkinsonian
  • 11.2. Drug-Induced Parkinsonism
  • 11.3. Genetic Parkinson's
  • 11.4. Idiopathic Parkinson's
  • 11.5. Vascular Parkinsonism

12. Parkinson's Disease Therapeutics Market, by Distribution Channel

  • 12.1. Offline
    • 12.1.1. Hospital Pharmacy
    • 12.1.2. Retail Pharmacy
  • 12.2. Online

13. Parkinson's Disease Therapeutics Market, by End User

  • 13.1. Clinics
  • 13.2. Home Care
  • 13.3. Hospitals

14. Parkinson's Disease Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Parkinson's Disease Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Parkinson's Disease Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. AbbVie Inc.
    • 17.3.2. Biogen Inc.
    • 17.3.3. Bristol-Myers Squibb Company
    • 17.3.4. Eisai Co., Ltd.
    • 17.3.5. Eli Lilly and Company
    • 17.3.6. F. Hoffmann-La Roche Ltd.
    • 17.3.7. GlaxoSmithKline plc
    • 17.3.8. Merck & Co., Inc.
    • 17.3.9. Otsuka Pharmaceutical Co., Ltd.
    • 17.3.10. Pfizer Inc.
    • 17.3.11. Teva Pharmaceutical Industries Limited
    • 17.3.12. Bayer AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 2. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
  • FIGURE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
  • FIGURE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 29. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 30. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 31. PARKINSON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. PARKINSON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PARKINSON'S DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY BENZTROPINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY BENZTROPINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY BENZTROPINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY BENZTROPINE, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY BENZTROPINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY BENZTROPINE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRIHEXYPHENIDYL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRIHEXYPHENIDYL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRIHEXYPHENIDYL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRIHEXYPHENIDYL, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRIHEXYPHENIDYL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRIHEXYPHENIDYL, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ENTACAPONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ENTACAPONE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ENTACAPONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ENTACAPONE, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ENTACAPONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ENTACAPONE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TOLCAPONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TOLCAPONE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TOLCAPONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TOLCAPONE, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TOLCAPONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TOLCAPONE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE AGONISTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE AGONISTS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE AGONISTS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY LEVODOPA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY LEVODOPA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY LEVODOPA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY LEVODOPA, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY LEVODOPA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY LEVODOPA, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO-B INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO-B INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO-B INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO-B INHIBITORS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO-B INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO-B INHIBITORS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DEEP BRAIN STIMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DEEP BRAIN STIMULATION, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DEEP BRAIN STIMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DEEP BRAIN STIMULATION, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SPEECH & LANGUAGE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SPEECH & LANGUAGE THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SPEECH & LANGUAGE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SPEECH & LANGUAGE THERAPY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SPEECH & LANGUAGE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SPEECH & LANGUAGE THERAPY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INFUSION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INFUSION, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INFUSION, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 125. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2025-2030 (USD MILLION)
  • TABLE 127. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ATYPICAL PARKINSONIAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ATYPICAL PARKINSONIAN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 129. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ATYPICAL PARKINSONIAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ATYPICAL PARKINSONIAN, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 131. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ATYPICAL PARKINSONIAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ATYPICAL PARKINSONIAN, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 133. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG-INDUCED PARKINSONISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG-INDUCED PARKINSONISM, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 135. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG-INDUCED PARKINSONISM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG-INDUCED PARKINSONISM, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 137. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG-INDUCED PARKINSONISM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG-INDUCED PARKINSONISM, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 139. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GENETIC PARKINSON'S, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GENETIC PARKINSON'S, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 141. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GENETIC PARKINSON'S, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GENETIC PARKINSON'S, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 143. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GENETIC PARKINSON'S, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GENETIC PARKINSON'S, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 145. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY IDIOPATHIC PARKINSON'S, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY IDIOPATHIC PARKINSON'S, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 147. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY IDIOPATHIC PARKINSON'S, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY IDIOPATHIC PARKINSON'S, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 149. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY IDIOPATHIC PARKINSON'S, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY IDIOPATHIC PARKINSON'S, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 151. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY VASCULAR PARKINSONISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY VASCULAR PARKINSONISM, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 153. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY VASCULAR PARKINSONISM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY VASCULAR PARKINSONISM, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 155. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY VASCULAR PARKINSONISM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY VASCULAR PARKINSONISM, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 157. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 159. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 161. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 163. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 165. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 167. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 169. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 171. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 173. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 175. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 177. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 179. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 181. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 183. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 185. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 187. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 189. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 191. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 193. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 195. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 197. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 199. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 201. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 203. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 205. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 207. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2030 (USD MILLION)
  • TABLE 209. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 211. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
  • TABLE 213. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 215. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 217. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 219. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 221. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2025-2030 (USD MILLION)
  • TABLE 223. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 225. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 227. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 229. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 231. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 233. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
  • TABLE 235. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 237. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 241. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 243. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2025-2030 (USD MILLION)
  • TABLE 245. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 247. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 249. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 251. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 253. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 255. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
  • TABLE 257. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 259. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 261. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 263. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 265. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2025-2030 (USD MILLION)
  • TABLE 267. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 269. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 271. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2030 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA P